Loading...
XNASEDAP
Market cap81mUSD
Dec 24, Last price  
2.19USD
1D
-1.35%
1Q
-25.00%
Jan 2017
-33.23%
Name

Edap Tms SA

Chart & Performance

D1W1MN
XNAS:EDAP chart
P/E
P/S
1.29
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
4.99%
Rev. gr., 5y
9.05%
Revenues
60m
+9.64%
22,146,62820,794,51020,265,17622,362,10523,053,00024,885,00023,708,00022,292,00026,065,00024,079,00026,785,00032,253,00035,611,00035,746,00039,182,00044,911,00041,662,00044,066,00055,109,00060,423,000
Net income
-21m
L+622.06%
00001,597,000-7,766,000-12,717,000-938,000-7,475,000-5,021,000-512,000-1,667,0003,842,000-681,000-338,0001,512,000-1,704,000700,000-2,933,000-21,178,000
CFO
-15m
L+385.38%
0000-4,593,000-3,664,000-3,818,000-737,000-162,000-2,495,000-1,014,0001,338,0001,119,000-3,059,000175,0003,800,0001,977,0004,445,000-3,024,000-14,678,000

Profile

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
IPO date
Aug 01, 1997
Employees
264
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
60,423
9.64%
55,109
25.06%
44,066
5.77%
Cost of revenue
80,235
59,367
45,677
Unusual Expense (Income)
NOPBT
(19,812)
(4,258)
(1,611)
NOPBT Margin
Operating Taxes
644
837
193
Tax Rate
NOPAT
(20,456)
(5,095)
(1,804)
Net income
(21,178)
622.06%
(2,933)
-519.00%
700
-141.08%
Dividends
Dividend yield
Proceeds from repurchase of equity
256
21,960
21,289
BB yield
-0.13%
-5.99%
-10.96%
Debt
Debt current
5,112
1,846
1,914
Long-term debt
5,720
6,031
7,566
Deferred revenue
264
440
Other long-term liabilities
3,717
2,710
2,533
Net debt
(32,639)
(55,259)
(36,805)
Cash flow
Cash from operating activities
(14,678)
(3,024)
4,445
CAPEX
(3,762)
(2,183)
(1,554)
Cash from investing activities
(4,344)
(2,378)
(1,638)
Cash from financing activities
(911)
21,741
20,266
FCF
(27,747)
(9,264)
(3,709)
Balance
Cash
43,471
63,136
47,183
Long term investments
(898)
Excess cash
40,450
60,381
44,082
Stockholders' equity
(63,185)
(41,425)
(38,638)
Invested Capital
132,249
122,467
99,326
ROIC
ROCE
EV
Common stock shares outstanding
36,997
34,393
32,423
Price
5.28
-50.47%
10.66
77.96%
5.99
15.86%
Market cap
195,343
-46.72%
366,625
88.77%
194,213
28.88%
EV
162,704
311,366
157,408
EBITDA
(17,899)
(2,653)
309
EV/EBITDA
509.41
Interest
232
168
52
Interest/NOPBT